LAVA THERAP. B.V. EO-12 (F:4PKB) — Market Cap & Net Worth
Market Cap & Net Worth: LAVA THERAP. B.V. EO-12 (4PKB)
LAVA THERAP. B.V. EO-12 (F:4PKB) has a market capitalization of $38.54 Million (€32.96 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #22813 globally and #2007 in its home market, demonstrating a 5.88% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LAVA THERAP. B.V. EO-12's stock price €1.44 by its total outstanding shares 26305295 (26.31 Million).
LAVA THERAP. B.V. EO-12 Market Cap History: 2021 to 2025
LAVA THERAP. B.V. EO-12's market capitalization history from 2021 to 2025. Data shows change from $123.01 Million to $44.29 Million (-35.84% CAGR).
LAVA THERAP. B.V. EO-12 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LAVA THERAP. B.V. EO-12's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4PKB by Market Capitalization
Companies near LAVA THERAP. B.V. EO-12 in the global market cap rankings as of May 5, 2026.
Key companies related to LAVA THERAP. B.V. EO-12 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
LAVA THERAP. B.V. EO-12 Historical Marketcap From 2021 to 2025
Between 2021 and today, LAVA THERAP. B.V. EO-12's market cap moved from $123.01 Million to $ 44.29 Million, with a yearly change of -35.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €44.29 Million | +50.79% |
| 2024 | €29.37 Million | -31.29% |
| 2023 | €42.75 Million | -57.36% |
| 2022 | €100.26 Million | -18.50% |
| 2021 | €123.01 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of LAVA THERAP. B.V. EO-12 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.54 Million USD |
| MoneyControl | $38.54 Million USD |
| MarketWatch | $38.54 Million USD |
| marketcap.company | $38.54 Million USD |
| Reuters | $38.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LAVA THERAP. B.V. EO-12
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage can… Read more